Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TriComB: Trifluridine/Tipiracil + Capecitabine + Bevacizumab in mCRC
NCT04564898Phase 2Active, not recruiting
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Jan 2022
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trifluridine + tipiracil in colorectal cancer (CRC), sponsored by Gruppo Oncologico Nord Ovest. Started Jan 2022; status: active, not recruiting.
02
Drugs
trifluridine + tipiracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04564898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04564898.